Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting.

BACKGROUND: Metabolomics is the rapidly evolving field of the comprehensive measurement of ideally all endogenous metabolites in a biological fluid. However, no single analytic technique covers the entire spectrum of the human metabolome. Here we present results from a multiplatform study, in which...

Full description

Bibliographic Details
Main Authors: Karsten Suhre, Christa Meisinger, Angela Döring, Elisabeth Altmaier, Petra Belcredi, Christian Gieger, David Chang, Michael V Milburn, Walter E Gall, Klaus M Weinberger, Hans-Werner Mewes, Martin Hrabé de Angelis, H-Erich Wichmann, Florian Kronenberg, Jerzy Adamski, Thomas Illig
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2010-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC2978704?pdf=render
_version_ 1818276322664775680
author Karsten Suhre
Christa Meisinger
Angela Döring
Elisabeth Altmaier
Petra Belcredi
Christian Gieger
David Chang
Michael V Milburn
Walter E Gall
Klaus M Weinberger
Hans-Werner Mewes
Martin Hrabé de Angelis
H-Erich Wichmann
Florian Kronenberg
Jerzy Adamski
Thomas Illig
author_facet Karsten Suhre
Christa Meisinger
Angela Döring
Elisabeth Altmaier
Petra Belcredi
Christian Gieger
David Chang
Michael V Milburn
Walter E Gall
Klaus M Weinberger
Hans-Werner Mewes
Martin Hrabé de Angelis
H-Erich Wichmann
Florian Kronenberg
Jerzy Adamski
Thomas Illig
author_sort Karsten Suhre
collection DOAJ
description BACKGROUND: Metabolomics is the rapidly evolving field of the comprehensive measurement of ideally all endogenous metabolites in a biological fluid. However, no single analytic technique covers the entire spectrum of the human metabolome. Here we present results from a multiplatform study, in which we investigate what kind of results can presently be obtained in the field of diabetes research when combining metabolomics data collected on a complementary set of analytical platforms in the framework of an epidemiological study. METHODOLOGY/PRINCIPAL FINDINGS: 40 individuals with self-reported diabetes and 60 controls (male, over 54 years) were randomly selected from the participants of the population-based KORA (Cooperative Health Research in the Region of Augsburg) study, representing an extensively phenotyped sample of the general German population. Concentrations of over 420 unique small molecules were determined in overnight-fasting blood using three different techniques, covering nuclear magnetic resonance and tandem mass spectrometry. Known biomarkers of diabetes could be replicated by this multiple metabolomic platform approach, including sugar metabolites (1,5-anhydroglucoitol), ketone bodies (3-hydroxybutyrate), and branched chain amino acids. In some cases, diabetes-related medication can be detected (pioglitazone, salicylic acid). CONCLUSIONS/SIGNIFICANCE: Our study depicts the promising potential of metabolomics in diabetes research by identification of a series of known and also novel, deregulated metabolites that associate with diabetes. Key observations include perturbations of metabolic pathways linked to kidney dysfunction (3-indoxyl sulfate), lipid metabolism (glycerophospholipids, free fatty acids), and interaction with the gut microflora (bile acids). Our study suggests that metabolic markers hold the potential to detect diabetes-related complications already under sub-clinical conditions in the general population.
first_indexed 2024-12-12T22:43:49Z
format Article
id doaj.art-bcb5d252a31940179a90efd756bcbc38
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-12T22:43:49Z
publishDate 2010-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-bcb5d252a31940179a90efd756bcbc382022-12-22T00:09:15ZengPublic Library of Science (PLoS)PLoS ONE1932-62032010-01-01511e1395310.1371/journal.pone.0013953Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting.Karsten SuhreChrista MeisingerAngela DöringElisabeth AltmaierPetra BelcrediChristian GiegerDavid ChangMichael V MilburnWalter E GallKlaus M WeinbergerHans-Werner MewesMartin Hrabé de AngelisH-Erich WichmannFlorian KronenbergJerzy AdamskiThomas IlligBACKGROUND: Metabolomics is the rapidly evolving field of the comprehensive measurement of ideally all endogenous metabolites in a biological fluid. However, no single analytic technique covers the entire spectrum of the human metabolome. Here we present results from a multiplatform study, in which we investigate what kind of results can presently be obtained in the field of diabetes research when combining metabolomics data collected on a complementary set of analytical platforms in the framework of an epidemiological study. METHODOLOGY/PRINCIPAL FINDINGS: 40 individuals with self-reported diabetes and 60 controls (male, over 54 years) were randomly selected from the participants of the population-based KORA (Cooperative Health Research in the Region of Augsburg) study, representing an extensively phenotyped sample of the general German population. Concentrations of over 420 unique small molecules were determined in overnight-fasting blood using three different techniques, covering nuclear magnetic resonance and tandem mass spectrometry. Known biomarkers of diabetes could be replicated by this multiple metabolomic platform approach, including sugar metabolites (1,5-anhydroglucoitol), ketone bodies (3-hydroxybutyrate), and branched chain amino acids. In some cases, diabetes-related medication can be detected (pioglitazone, salicylic acid). CONCLUSIONS/SIGNIFICANCE: Our study depicts the promising potential of metabolomics in diabetes research by identification of a series of known and also novel, deregulated metabolites that associate with diabetes. Key observations include perturbations of metabolic pathways linked to kidney dysfunction (3-indoxyl sulfate), lipid metabolism (glycerophospholipids, free fatty acids), and interaction with the gut microflora (bile acids). Our study suggests that metabolic markers hold the potential to detect diabetes-related complications already under sub-clinical conditions in the general population.http://europepmc.org/articles/PMC2978704?pdf=render
spellingShingle Karsten Suhre
Christa Meisinger
Angela Döring
Elisabeth Altmaier
Petra Belcredi
Christian Gieger
David Chang
Michael V Milburn
Walter E Gall
Klaus M Weinberger
Hans-Werner Mewes
Martin Hrabé de Angelis
H-Erich Wichmann
Florian Kronenberg
Jerzy Adamski
Thomas Illig
Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting.
PLoS ONE
title Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting.
title_full Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting.
title_fullStr Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting.
title_full_unstemmed Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting.
title_short Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting.
title_sort metabolic footprint of diabetes a multiplatform metabolomics study in an epidemiological setting
url http://europepmc.org/articles/PMC2978704?pdf=render
work_keys_str_mv AT karstensuhre metabolicfootprintofdiabetesamultiplatformmetabolomicsstudyinanepidemiologicalsetting
AT christameisinger metabolicfootprintofdiabetesamultiplatformmetabolomicsstudyinanepidemiologicalsetting
AT angeladoring metabolicfootprintofdiabetesamultiplatformmetabolomicsstudyinanepidemiologicalsetting
AT elisabethaltmaier metabolicfootprintofdiabetesamultiplatformmetabolomicsstudyinanepidemiologicalsetting
AT petrabelcredi metabolicfootprintofdiabetesamultiplatformmetabolomicsstudyinanepidemiologicalsetting
AT christiangieger metabolicfootprintofdiabetesamultiplatformmetabolomicsstudyinanepidemiologicalsetting
AT davidchang metabolicfootprintofdiabetesamultiplatformmetabolomicsstudyinanepidemiologicalsetting
AT michaelvmilburn metabolicfootprintofdiabetesamultiplatformmetabolomicsstudyinanepidemiologicalsetting
AT walteregall metabolicfootprintofdiabetesamultiplatformmetabolomicsstudyinanepidemiologicalsetting
AT klausmweinberger metabolicfootprintofdiabetesamultiplatformmetabolomicsstudyinanepidemiologicalsetting
AT hanswernermewes metabolicfootprintofdiabetesamultiplatformmetabolomicsstudyinanepidemiologicalsetting
AT martinhrabedeangelis metabolicfootprintofdiabetesamultiplatformmetabolomicsstudyinanepidemiologicalsetting
AT herichwichmann metabolicfootprintofdiabetesamultiplatformmetabolomicsstudyinanepidemiologicalsetting
AT floriankronenberg metabolicfootprintofdiabetesamultiplatformmetabolomicsstudyinanepidemiologicalsetting
AT jerzyadamski metabolicfootprintofdiabetesamultiplatformmetabolomicsstudyinanepidemiologicalsetting
AT thomasillig metabolicfootprintofdiabetesamultiplatformmetabolomicsstudyinanepidemiologicalsetting